Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis.

ABSTRACT: Additional studies are needed to confirm whether the use of renin-angiotensin system blockers (RASBs) induces survival benefits in patients on hemodialysis (HD). This study aimed to evaluate patient survival with the use of RASBs in a large sample of maintenance HD patients. This study used data from the national HD quality assessment program and claim data from South Korea (n = 54,903). A patient using RASBs was defined as someone who had received more than one prescription during the 6 months of each HD quality assessment period. The patients were divided into three groups as follows: Group 1, no prescription for anti-hypertensive drugs; Group 2, prescription for anti-hypertensive drugs other than RASBs; and Group 3, prescription for RASBs. The five-year survival rates in Groups 1

SUBMITTER: Kang SH 

PROVIDER: S-EPMC10179028 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature